Emily Olsen
The service, to debut in the coming weeks, will include telehealth consultations and antiviral drug prescriptions.
The service is now available in some markets, but the companies plan to expand to additional cities.
The InVisionOS officially received the clearance earlier this month and will be available in early 2022.
The life science company plans to launch its open research tool in 2022.
The companies position the acquisition as a way to reduce costs for patients and improve the financial health of provider organizations.
The CHIME Digital Health Most Wired survey found 26% of healthcare organizations reported a quarter or more of their patients have used telehealth, compared with only 7% in 2019.
The Series C brings its total raise to $160 million.
The resignation comes a week after the company announced its cofounders were leaving their roles.
The news comes just as Pear is finalizing its SPAC merger.
SWORD raised $163 million in Series D funding, which allowed for a secondary round where it scooped up another $26 million.